Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial
All patients will provide informed consent. REMODEL was registered on ClinicalTrials.gov (NCT06101095) on October 19, 2023.
Authors
- Bram P. Raphael (ORCID: https://orcid.org/0000-0003-4031-5974)
- James T. Angello (ORCID: https://orcid.org/0000-0002-7714-7073)
- Evan S. Dellon (ORCID: https://orcid.org/0000-0003-1167-1101)
- Albert Jan Bredenoord (ORCID: https://orcid.org/0000-0001-5918-2062)
- Sherif Zaghloul
- Edoardo Vincenzo Savarino (ORCID: https://orcid.org/0000-0002-3187-2894)
- Mei Zhang (ORCID: https://orcid.org/0000-0002-3916-9925)
- Amr Radwan (ORCID: https://orcid.org/0000-0003-1658-5229)
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Padua (IT)
- Regeneron (United States) (US)
- Morristown Medical Center (US)
- C3I (United States) (US)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/17562848251383782
- Citations
- 2
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Sanofi
- Regeneron Pharmaceuticals